PRME
Prime Medicine Inc

2,639
Mkt Cap
$628.32M
Volume
2.19M
52W High
$6.94
52W Low
$1.11
PE Ratio
-2.53
PRME Fundamentals
Price
$3.39
Prev Close
$3.48
Open
$3.55
50D MA
$3.77
Beta
2.16
Avg. Volume
2.93M
EPS (Annual)
-$1.35
P/B
5.20
Rev/Employee
$31,726.03
$454.94
Loading...
Loading...
News
all
press releases
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step PR Newswire VANCOUVER, BC, March 31, 2026 Issued on behalf of Ava Bio...
PR Newswire·21h ago
News Placeholder
More News
News Placeholder
Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the company, Marketbeat reports. One...
MarketBeat·2d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3% - What's Next?
Prime Medicine (NASDAQ:PRME) Trading Down 7.3% - What's Next...
MarketBeat·5d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Trading Up 5.6% - Time to Buy?
Prime Medicine (NASDAQ:PRME) Trading 5.6% Higher - Still a Buy...
MarketBeat·6d ago
News Placeholder
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
Advanced Cell-based Therapy Booming the Success for Healthcare Sector Advanced Cell-based Therapy Booming the Success for Healthcare Sector PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf...
PR Newswire·8d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Shares Gap Up - Here's Why
Prime Medicine (NASDAQ:PRME) Shares Gap Up - What's Next...
MarketBeat·20d ago
News Placeholder
Prime Medicine (NYSE:PRME) Shares Gap Up - Should You Buy?
Prime Medicine (NYSE:PRME) Shares Gap Up - Should You Buy...
MarketBeat·20d ago
News Placeholder
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer
Oppenheimer assumed coverage on Prime Medicine in a research note on Thursday. They set an "outperform" rating and a $11.00 price objective on the stock...
MarketBeat·20d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Trading Down 6.3% - Here's What Happened
Prime Medicine (NASDAQ:PRME) Shares Down 6.3% - Here's What Happened...
MarketBeat·21d ago
News Placeholder
Prime Medicine (NYSE:PRME) Shares Down 6.9% - Here's What Happened
Prime Medicine (NYSE:PRME) Trading Down 6.9% - Here's Why...
MarketBeat·21d ago
<
1
2
...
>

Latest PRME News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.